Abstract
Age-related neurocognitive disorders are common problems in developed societies. Aging not only affects memory processes, but may also disturb attention, vigilance, and other executive functions. In the present study, we aimed to investigate age-related cognitive deficits in rats and associated molecular alterations in the brain. We also aimed to test the effects of the alpha7 nicotinic acetylcholine receptor (nAChR) agonist PHA-543613 on memory as well as on the sustained attention and vigilance of aged rats. Short- and long-term spatial memories of the rats were tested using the Morris water maze (MWM) task. To measure attention and vigilance, we designed a rat version of the psychomotor vigilance task (PVT) that is frequently used in human clinical examinations. At the end of the behavioral experiments, mRNA and protein expression of alpha7 nAChRs, cytokines, and brain-derived neurotrophic factor (BDNF) were quantitatively measured in the hippocampus, frontal cortex, striatum, and cerebellum. Aged rats showed marked cognitive deficits in both the MWM and the PVT. The deficit was accompanied by increased IL-1beta and TNFalpha mRNA expression and decreased BDNF protein expression in the hippocampus. PHA-543613 significantly improved the reaction time of aged rats in the PVT, especially for unexpectedly appearing stimuli, while only slightly (non-significantly) alleviating spatial memory deficits in the MWM. These results indicate that targeting alpha7 nAChRs may be an effective strategy for the amelioration of attention and vigilance deficits in age-related neurocognitive disorders.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Aging is a complex and multifactorial process induced by the multifaceted interaction of genetic, epigenetic, and environmental factors, and it appears as a consequence of the action of time on living organisms [1]. During aging, the functional capabilities of the brain decline progressively, which generally affects cognitive performance, including attention, speed of information processing, short-term (working) memory, long-term memory, and executive functions [2].
Advancing age is the strongest known risk factor for most neurodegenerative disorders, including disorders of the mind termed neurocognitive disorders (NCDs), as the prevalence of these conditions increases significantly with age even without other identifiable risks [3]. Despite its central role in the pathogenesis of NCDs, the role of aging of the brain has not been fully understood at cellular and molecular levels [4]. Therefore, to develop successful diagnostic tools and therapeutic interventions, it is important to consider the basic cross-species hallmarks of aging at the cellular and molecular levels in various tissues and their causal role in the onset and progression of NCDs in humans, as well as in preclinical (translational) model organisms [5].
Similar to the hallmarks of aging in other tissues, the aging brain also shows mitochondrial dysfunction, dysregulated energy metabolism, compromised DNA repair, aberrant neuronal network activity, dysregulated Ca2+ handling, and inflammation [6]. The activation of microglia and astrocytes is one of the fundamental events in the progressive neuroinflammation associated with aging, often termed inflammaging [7]. Microglia readily transform into an activated state in the aged brain, which is characterized by their amoeboid morphology in response to neuronal injuries or neurodegeneration and by the excessive production of proinflammatory cytokines, including interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNFalpha), which have detrimental effects on brain health, particularly during the aging process. [6, 8].
The aging of the brain is also generally associated with increased neuronal vulnerability, which differentially affects the different brain areas and associated neurotransmitter systems. For instance, the cholinergic system becomes particularly vulnerable during aging and undergoes moderate to severe degenerative remodeling in the basal forebrain, resulting in marked cell loss and hypofunction [9, 10]. There is a clear relationship between cholinergic hypofunction and a decline in cognitive functions, especially attention, learning, and memory. Furthermore, the administration of cholinergic agonists to animals and elderly human subjects has been suggested to result in a moderate improvement in various cognitive functions [11, 12]. Alpha7 nicotinic acetylcholine receptors (nAChR) are highly expressed in the nervous system, mostly in regions involved in cognition and memory processes (prefrontal cortex, hippocampus) and their dysfunction has been associated with several neurocognitive and neuropsychiatric disorders [13,14,15]. Furthermore, besides being abundant in neurons of memory-relevant cortical areas, alpha7 nAChRs are also expressed in microglia and astrocytes and significantly affect their polarization, antigen presentation, and cytokine production [16]. Therefore, alpha7 nAChR-specific agents have been brought into the focus of drug development for the treatment of NCDs both in preclinical model organisms and in clinical trials [17, 18].
In line with the above, the current study aimed to investigate both behavioral and molecular-level (mRNA and protein expression) alterations in the aged rat brain and to assess the effectiveness of an alpha7 nAChR-targeting cognitive enhancer treatment to predict the beneficial role of pharmacological alpha7 nAChR-modulation in pathological aging. Therefore, we first determined the cognitive deficits of aged rats using the Morris water maze (MWM) and the psychomotor vigilance task (PVT). Then, we investigated the effects of an alpha7 nAChR orthosteric agonist on spatial memory and vigilance in the aged rats. After the behavioral pharmacological studies, we assessed the mRNA and protein expression of IL-1beta, IL-6, TNFalpha, BDNF, NFkappaB, and alpha7 nAChR in key areas of the brain.
Materials and Methods
Animals
Male Lister hooded rats (EnVigo, Horst, Netherlands) were used in the present study. Aged animals were courtesy of Gedeon Richter Plc., where they participated in behavioral pharmacological experiments. They spent at least 6 months accommodating to our animal house before the experiments started. Morris water maze experiments were started with 36 naturally aged (25 months old) and 20 young adult (6 months old) rats. Twelve aged and twelve young rats were trained for the PVT. The PVT training started when aged rats were 31 months old and young adult rats were 12 months old, and the training lasted 2 months. Thus, aged rats were 33 months old, and young adult rats were 14 months old when the PVT experiments comparing the performance of aged and young rats were conducted. Then, the number of aged animals rapidly decreased between the ages of 33 and 34 months because of natural death. At the end of the experiments, aged rats were 34 months old, while young adult rats were 15 months old when 4 aged and 4 young adult rats were sacrificed for the analysis of brain samples using PCR and ELISA assays.
During the entire study, the animals were pair-housed under a 12/12 h daily light/dark cycle with controlled temperature and humidity in the animal house of the Szentágothai Research Centre, University of Pécs, Hungary. In the animal house, lights were ON from 7 a.m. to 7 p.m., and the animals were tested during the light ON period. Rats were fed daily with a controlled amount of food (17 g/animal laboratory chow, Ssniff Rat/Mouse Maintenance chow, Ssniff Spezialdiäten GmbH, Soest, Germany) to prevent the development of obesity and other related health problems. Water was available ad libitum. The experiments were approved by the Animal Welfare Committee of the University of Pécs and the National Scientific Ethical Committee on Animal Experimentation (ÁTET) of the Ministry of Agriculture (ethical license no.: BA02/2000–25/2015). All procedures fully complied with Decree No. 40/2013. (II. 14.) of the Hungarian Government and the EU Directive 2010/63/EU on the Protection of animals used for scientific purposes.
Morris water maze task
First, the spatial memory performance of aged and young rats was compared using the Morris water maze task (MWM). After confirming the memory deficit of aged rats in the first MWM experiment compared to young rats, a new experiment was designed to test the effects of the alpha7 nAChR agonist PHA-543613 on the memory performance of the same aged rats in the MWM.
The protocol of the MWM task was the same as described in previous reports from our laboratory [19, 20]. The task is represented in Supplementary Fig. 1A. In brief, experiments were carried out in a blue circular pool, 180 cm in diameter and 90 cm in height (Ugo Basile, Gemonio, Italy), filled to a depth of 30 cm with blue-painted, opaque water containing 500 g milk powder and 30 ml blue food coloring. The area of the pool was divided into four virtual quadrants (NW, SW, SE, NE). The experiments were recorded using Ethovision XT10 software (Noldus, Wageningen, Netherlands).
The experimental protocol started with daily training sessions for four consecutive days (with one 4-trial session each day), when a platform was placed in the center of one of the quadrants (submerged 1 cm below the surface), and the rats had to learn the location of the hidden platform with the help of visual cues placed around the maze. In the first MWM experiment (comparing aged and young rats), the platform was placed in the SW quadrant. In each trial, the rats were placed in different quadrants changed clockwise from trial to trial (starting points: N, E, S, W), and were allowed to search for the hidden platform for 2 min. During the trials, we measured the escape latency, which is the time elapsed until the animal found the platform. Furthermore, the swimming path length was also analyzed on training days using Ethovision XT10 software. If the platform was not found during the trial, the rat was placed on the platform for 10 s, and 2 min was recorded as escape latency. The performance of the animals on the first training day was used to evaluate their short-term memory performance, and changes in their average daily performance represented the learning process. On the fifth day, a single probe trial was performed to test the recall of long-term memory, when the platform was removed from the pool and the animals were allowed to search the pool for 2 min. During the probe trial, the time spent in the target quadrant (the quadrant where the platform was located during the training sessions) was measured as an index of long-term memory recall. Before the second MWM experiment testing the effects of PHA-543613, three more MWM sessions were run for the purpose of extinction of the memory trace for the earlier location of the platform. The extinction trials were run in the same manner as the probe trial.
Next, the effects of PHA-543613 were tested in the MWM using a between-subject design. Aged animals were treated on each of the four consecutive training days with one of the following treatments 45 min prior to testing: saline (A_VEH), 1.0 mg/kg PHA-543613 (A_PHA1), 3.0 mg/kg PHA-543613 (A_PHA3). Young control rats were treated with saline only (Y_VEH). The solutions were applied at 1 ml/kg dosing volume. The effects of PHA-543613 were evaluated in four training days (when the platform was hidden in the NE quadrant) and in a probe trial conducted on the fifth consecutive day (when the platform was absent).
Psychomotor vigilance task
The psychomotor vigilance task (PVT) was conducted as described in a recent study from our laboratory [21]. The apparatus and the task protocol are represented in Supplementary Fig. 1B and C, respectively. In brief, for conditioning, we used a standardized operant conditioning apparatus for rats (Habitest System, Coulbourn Instruments, Holliston, MA), equipped with stimulus generators (feeder light, color LED lights), response sensors (levers, photocell) and reward pellet delivery modules (feeder with delivery trough). Twelve aged and twelve young rats were gradually trained in a 10-step procedure (detailed in the Supplementary Material) to fully perform the PVT. All of the animals were successfully trained for the PVT.
Every trial of a PVT session was run as follows: rats were required to respond to the onset of the centrally located feeder light module by nose-poking into the pellet delivery trough of the feeder module. Then, the rats had to hold their nose in the delivery trough until the feeder light was turned off (fixation). The fixation time (foreperiod) varied randomly between 0 and 5000 ms. At the end of the foreperiod, the feeder light turned off and the color LED lights were illuminated above the two levers located left and right to the central feeder module serving as a cue signal for the rats to pull their nose out of the pellet delivery trough and press one of the levers within 10 s. After the lever press response, rats immediately received a reward pellet (45 mg dustless precision pellet, Bio-Serv, Flemington, NJ), the color LED lights were also turned off, and an intertrial interval (ITI) of 15 s started. If the animal correctly accomplished the given trial, the total reaction time (RT) was measured as the time from the offset of the feeder light (onset of the cue lights) until the lever press response. In the analysis, RT was split into two parts: 1) the time from the cue (feeder light off, color LEDs on) until pulling the nose out of the pellet delivery trough was considered as a decision phase of the response and was referred to as “noseout” time; while 2) the time from pulling the nose out until pressing the lever was considered as a mainly motor part of the response and was referred to as “pressing speed”. If the trial was not correctly performed, 3 different kinds of errors were defined and registered. If the animal did not put its nose in the feeder trough within 10 s after the onset of the feeder light, the trial was not initiated, and it was considered a “missed trial”. If the animal nose-poked but removed its head from the feeder trough before the offset of the feeder light, a “premature response” was recorded. If the animal succeeded the foreperiod but did not press the lever after the onset of the cue lights, it was considered an “omission error or lapse”. All types of errors resulted in the offset of all light stimuli and a 5 s extra timeout (punishment) period followed by the normal ITI of 15 s. In each experimental session, rats performed the task for 60 min or until 90 initiated trials were reached.
The performance of aged and young rats was compared in 3 sessions on 3 different days, and the recorded data was averaged between testing days. At this part of the study, aged rats were 33 months old, and young rats were 14 months old. Then, the effects of alpha7 nAChR agonist PHA-543613 on the performance of aged rats were tested in a within-subject experimental design. The aged rats performed four PVT sessions and the following treatments were applied in a randomized counter-balanced latin-square design: saline (VEH), 0.3 mg/kg PHA-543613 (PHA0.3), 1.0 mg/kg PHA-543613 (PHA1.0), 3.0 mg/kg PHA-543613 (PHA3.0).
Brain tissue collection and preparation
After completing the behavioral experiments, animals were anesthetized with an overdose of pentobarbital (800 mg/kg, i.p.) and were transcardially perfused. Four young and four aged rats were perfused with 0.9% saline, their brains were rapidly removed and were bilaterally dissected to the following brain areas: cerebellum (CER), hippocampus (HC), striatum (STR), and neocortex (CTX, frontal lobe). The dissected brain samples were frozen immediately in liquid nitrogen and were stored at -80 °C until biochemical analyses were performed.
Protein isolation and ELISA test
Total protein from the different brain regions was isolated in RIPA lysis buffer (50 mM Tris–HCl, pH: 8.0, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 5 mM EDTA, 0.1% SDS) with the addition of protease inhibitor cocktail (Sigma-Aldrich). The total protein concentrations of the samples were measured using a BCA Protein Assay kit (Pierce, Rockford, IL). Quantification of IL-1beta, BDNF, and alpha7 nAChR was carried out using Abbexa (Cambridge, UK) ELISA kits with the following catalog numbers, respectively: abx155713, abx155251, abx556026. ELISAs were performed according to the manufacturer’s protocols. Immediately after developing the final color reaction of the assay, the absorbance was measured at 450 nm with an iEMS Reader microplate reader (Thermo Fisher Scientific).
RNA isolation and quantitative RT-PCR measurements
The total RNA of the brain samples was extracted according to the manufacturer’s protocol by applying the NucleoSpin RNA kit (Macherey–Nagel, Düren, Germany). The quality and quantity of RNA were assessed at 260 nm using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, USA). The cDNA was constructed from total RNA with High Capacity cDNA reverse transcription kit (Thermo Fisher Scientific) in 20 μl reactions using random hexamers following the manufacturer’s protocol. The resulting cDNA was stored at − 20 °C. Target gene expressions were measured by real-time PCR using Maxima SYBRGreen MasterMix (Applied Biosystems, Waltham, USA) with an ABI Prism 7500 instrument (Applied Biosystems). The cDNAs were applied as a template for the amplification reactions. All samples were tested in duplicates. Primers were designed in Primer Express software (Thermo Fisher Scientific) considering the exon–intron boundaries for all target genes (Table 1). Cyclophilin A (CycA) was used as a housekeeping gene for the quantification of RNA. The thermal profile started at 95 ºC for 10 min, 40 cycles of 35 s at 95 ºC, 35 s at 60 ºC, and 1 min at 72 ºC.
Data analysis and statistics
Data analysis and statistical tests were made in Microsoft Excel and Jamovi 2.2.5 [22].
In the MWM, training day performance was expressed as the time needed to find the platform (escape latency) and was analyzed using repeated-measures ANOVA with TRIALS or DAYS as a within-subject factor and AGE as a between-subject factor. Performance in probe trials (including extinction training) was expressed as the time spent in the target quadrant (where the platform was earlier located) and was analyzed using independent samples t-test or one-way ANOVA following post-hoc LSD tests.
In the PVT, total reaction time and its components as well as the number of premature errors were averaged over all trials or trials with a given range of foreperiod length. In the latter case, performance was analyzed as a function of foreperiod length using a linear mixed-effects model. Data averaged over all trials were analyzed using independent samples t-test (aged vs. young) or linear mixed-effects model (effects of different doses of PHA-543613) with animal identity as a random intercept. The omnibus test of the linear mixed-effects model was followed by LSD post-hoc comparison.
Protein concentrations measured in the brains of aged and young rats were compared using independent samples t-test. Quantitative PCR data were expressed as arbitrary units that indicate the mRNA expression of target genes normalized to CycA housekeeping gene and were analyzed using independent samples t-test.
After omnibus tests (i.e., ANOVA and linear mixed-effects model) pairwise comparisons were made between the levels when the main effect showed at least a tendency (p < 0.1) to a significant effect. Pairwise comparisons were considered significant if p < 0.05.
Results
Morris Water Maze test
Spatial memory performance of aged and young adult rats
In the first MWM experiment, the memory performance of aged and young adult rats was compared (Fig. 1). One aged rat was excluded from the study because it could not swim. On the first training day, aged rats performed overall worse than young rats as they needed significantly more time to find the hidden platform (AGE: F(1, 53) = 4.967, p = 0.030; Fig. 1A). The difference between the performance of aged and young rats further increased during the consecutive training days (Fig. 1B). Aged rats showed less improvement during training days than young rats as the learning curve of young rats was significantly steeper than that of aged rats (DAY × AGE: F(3, 159) = 7.571, p < 0.001). The overall performance of aged rats on the four training days was also significantly worse compared to young rats (AGE: F(1, 53) = 71.004; p < 0.001). Furthermore, aged rats also showed significant long-term memory deficits in the probe trial (Fig. 1C), when they searched the platform in the target quadrant for a shorter time than young rats (t(53) = − 5.991, p < 0.001). The results of the extinction training (Fig. 1D) also confirmed that aged rats poorly learned the location of the platform. During the four sessions, when the platform was absent, young rats spent gradually less time day by day searching the platform in its previous location, while the time spent in the target quadrant decreased in a significantly smaller extent in the case of aged rats (DAY × AGE: F(3, 156) = 11.570, p < 0.001). Eventually, both aged and young rats spent almost equal time in the target quadrant (indicating complete extinction of their searching behavior in the previous location of the platform), but in the case of aged rats the time spent in the target quadrant was only slightly less than in the probe trial, also indicating their impaired spatial learning. In summary, short-term memory, learning (acquisition), and long-term memory (recall) were all found impaired in aged rats in the MWM task.
Effects of PHA-543613 on the spatial memory of aged rats
Next, we tested the effects of alpha7 nAChR agonist PHA-543613 on the performance of aged rats in the MWM (Fig. 2). Results of the first training day (Fig. 2A) showed that the short-term memory performance of young adult rats was significantly better than that of other groups (TRIAL × AGE: F(9,150) = 2.600, p = 0.008). Only young rats improved from trial to trial on the first day (F(3, 54) = 13.760, p < 0.001), aged rats showed no improvement regardless of the applied treatments (A_VEH: F(3, 33) = 0.448, p = 0.720; A_PHA1: F(3, 33) = 0.691, p = 0.564; A_PHA3: F(3, 30) = 1.334, p = 0.282). Although all four groups showed improvement during the four consecutive training days (Fig. 2B), the overall performance (average escape latency) of the animals was different depending on their age and the applied treatments (GROUP: F(3, 50) = 5.536, p = 0.002). Young rats found the platform significantly faster than aged rats treated with vehicle or 1.0 mg/kg PHA-543613 (Y_VEH vs. A_VEH: p = 0.018, Y_VEH vs. A_PHA1: p < 0.001). However, no significant difference was found between the overall escape latency of young rats and aged rats treated with 3.0 mg/kg PHA-543613 (Y_VEH vs. A_PHA3: p = 0.065). On the other hand, no significant difference was found between the escape latency of vehicle-treated and PHA-543613-treated aged rats. On the fifth experimental day, the long-term spatial memory of the rats was tested in a probe trial, when the platform was absent (Fig. 2C). Young rats spent significantly more time seeking the platform in the target quadrant than aged rat groups treated with vehicle or 1.0 mg/kg PHA-543613 (F(3, 50) = 4.850, p = 0.005; Y_VEH vs. A_VEH: p < 0.001; Y_VEH vs. A_PHA1: p = 0.010). However, there was no significant difference between the performance of aged rats treated with 3.0 mg/kg PHA-543613 and young rats (Y_VEH vs. A_PHA3: p = 0.094). On the other hand, no significant difference was found in the time spent in the target quadrant between vehicle-treated and PHA-543613-treated aged rats. In the probe trial, the swimming speed of the rats was also compared, and we found that there was no difference between the swimming speed of young, vehicle-treated aged, and PHA-543613-treated aged rats indicating that PHA-543613 did not exert its effect through the general increase of locomotor speed of animals. In summary, different measurement endpoints of the MWM task initially showed marked cognitive (memory performance) deficit in aged rats which was only slightly alleviated by the high but not the low dose of PHA-543613.
Psychomotor Vigilance Task
Comparison of PVT performance of aged and young adult rats
Out of the 12 aged rats that were trained for the PVT, two rats showed very low motivation and performed an insufficient number of correct trials. Therefore, these two animals were excluded from the analysis. Aged rats responded to the randomly timed stimuli significantly slower than young rats (t(19) = 4.082, p < 0.001, Fig. 3A-B). Analysis of the reaction time as a function of the foreperiod showed typical effects of expectation for stimuli appearing after a longer foreperiod compared to unexpectedly rapid stimuli (Fig. 3A). Namely, reaction time showed a gradual decrease between 0 to 1.5 s foreperiod (F(9, 168.1) = 12.145, p < 0.001; 0–0.5 vs. 0.5–1.0 s: p < 0.001; 0.5–1.0 vs. 1.0–1.5 s: p = 0.006). However, increasing the foreperiod over 1.5 s did not result in any further decrease in reaction time (1.0–1.5 vs. 1.5–2.0 s: p = 0.680) indicating that the maximal speed of rats for responding to the stimulus was already reached. The stimulus expectation (foreperiod) effect was detected both in aged and young rats as no interaction was found between the effects of foreperiod length and age (FOREPERIOD × AGE: F(9, 168.1) = 0.586, p = 0.807). Thus, age did not affect the ability of rats to respond faster to expected (late) stimuli and did not affect the length of foreperiod where the maximum speed of responses was reached. Similarly, the expectation effect was detected in both age groups when only the decision phase (“noseout” response) of the reaction time was analyzed (FOREPERIOD: F(9, 168.1) = 10.701, p < 0.001; FOREPERIOD × AGE: F(9, 168.1) = 0.917, p = 0.512; Fig. 3C). Analysis of the “noseout” time confirmed the deficit of aged rats to respond to the stimuli as the decision phase of the reaction time was also significantly slower than in young rats (t(19) = 3.004, p = 0.007; Fig. 3D). However, the motor phase of the responses (“lever-pressing”) was differently influenced by the foreperiod in aged and young rats (FOREPERIOD × AGE: F(9, 168) = 2.483, p = 0.011; Fig. 3E). The lever-pressing time of young rats slightly decreased for stimuli preceded by long foreperiods indicating the development of an expectation of the forthcoming cue signal (F(9, 90) = 3.076, p = 0.003). Such expectation effect was completely absent in the motor phase of responses of aged rats (F(9, 78) = 1.705, p = 0.102). Furthermore, aged rats pressed the lever significantly slower than young rats (F(1, 19) = 11.060, p = 0.004), thus, aged rats exhibited a marked decline in the speed of motor execution, too.
Slower responses of aged rats were also accompanied by more premature errors (t(19) = 2.260, p = 0.036; Fig. 3H) indicating that aged rats badly tolerated long waiting times for the appearance of the cue stimuli. Furthermore, aged rats initiated fewer trials than young rats, possibly indicating their declined motivation and/or increased mental fatigue (t(19) = 3.186, p = 0.005, Fig. 5A). The number of omission errors was not statistically evaluated since both aged and young rats made very few or (mostly) no omission errors.
Effects of PHA-543613 on the performance of aged rats in the PVT
Results of the second PVT experiment that investigated the effects of alpha7 nAChR agonist PHA-543613 on the cognitive performance of aged rats are summarized in Fig. 4. The experiment was conducted on 5 aged animals. The alpha7 nAChR agonist dose-dependently improved the reaction time of aged rats in the PVT (F(3, 12) = 2.877, p = 0.080) since 1.0 mg/kg and 3.0 mg/kg doses of PHA-543613 decreased the overall reaction time of aged rats compared to the treatment with vehicle (PHA1.0 vs. VEH: p = 0.041; PHA3.0 vs. VEH: p = 0.027). Interaction between the FOREPERIOD × TREATMENT factors showed that the effects of the treatments were dependent on the length of the foreperiod (F(27, 101.2) = 2.054; p = 0.005). Statistical data from the analysis of reaction time and its components in different ranges of the foreperiod length are summarized in Table 2. PHA-543613 improved the responsiveness of aged rats mainly for unexpected stimuli: reaction time in trials with 0–0.5 s foreperiod was significantly improved by all applied doses of PHA-543613, whereas reaction time in trials with 0.5–1.0 s foreperiod was only improved by the 1.0 mg/kg and 3.0 mg/kg doses of PHA-543613, while only a tendency was found for reaction time improvement after the treatment with 0.3 mg/kg dose of PHA-543613. Analysis of the decision phase of reaction time indicated similar interaction between effects (FOREPERIOD × TREATMENT: F(27, 101) = 2.192, p = 0.003), as “noseout” time was decreased by all doses of PHA-543613 in trials with 0–0.5 s foreperiod, and by 1.0 mg/kg and 3.0 mg/kg PHA-543613 in trials with 1.0–1.5 s foreperiod. PHA-543613 also showed a tendency to improve the overall speed of motor execution as the 3.0 mg/kg dose significantly decreased “lever-pressing” time (F(3, 12) = 2.813, p = 0.084; PHA3.0 vs. VEH: p = 0.017). The interaction between the foreperiod length and treatment with PHA-543613 in “lever-pressing” speed showed only a tendency to the significance level (FOREPERIOD × TREATMENT: F(27, 99) = 1.451, p = 0.095).
In summary, the treatment with PHA-543613 resulted in a global improvement of the reaction time (both in the decision and motor phases) of aged rats. However, PHA-543613 did not affect the number of premature responses (F(3, 12) = 1.462, p = 0.274) or the number of missed trials (F(3, 12) = 1.413, p = 0.287, Fig. 5B).
Protein and mRNA expression levels of neuroimmune factors and alpha7 nAChRs in the brain of aged and young rats
Results of RT-PCR measurements indicated that the cognitive deficit of aged rats that was seen in both the MWM and the PVT was also accompanied by the increase in the occurrence of neuroinflammatory markers in the brain (Fig. 6). Namely, mRNA expression of major inflammatory factors IL-1β and TNFα were significantly upregulated in the hippocampus of aged rats compared to young adults (IL-1β: t(6) = − 4.316, p = 0.005; TNFα: t(6) = − 3.759, p = 0.009). However, there was no difference in the expression of NFκB and IL-6 in any of the examined brain regions. Furthermore, the level of BDNF protein in the hippocampus was lower in aged rats than in young rats (t(6) = 2.514, p = 0.046, Fig. 7). We did not find any differences in the brain expression of alpha7 nAChRs either in the mRNA or in the protein levels.
Discussion
In summary, aged rats in the present study showed marked cognitive deficit in comparison with young adult rats both in the MWM task that tested spatial memory performance and in the PVT that tested vigilance and sustained attention of the rats. Aged rats reportedly underperform in other tasks measuring sustained attention like the 5-choice serial reaction time task [23], which was confirmed by our present results in the PVT. Furthermore, patients with Alzheimer’s disease or frontotemporal lobar degeneration also show impaired performance in the PVT, which is mainly manifested in the high number of omission errors or lapses (RT > 500 ms) [24]. In the rat PVT, omission errors are slightly differently defined than in the human PVT since the rats have to succeed in a fixation period which is usually not the case in the human PVT. Therefore, omission errors in human PVT may be considered an analog of the missed trials in the rat PVT. In the number of missed trials, aged rats performed badly similarly to aged humans. Thus, testing aged rats in the PVT may be a relevant preclinical model of cognitive deficits in age-related neurological and psychiatric diseases.
The cognitive impairment of aged rats was accompanied by increased mRNA expression of neuroinflammatory factors such as IL-1beta and TNFalfa and by a decrease in the protein expression of neurotrophic factor BDNF. Notably, a limitation of the present study is that the pharmacological experiment on aged rats ended only one day before the collection of brain samples. Thus, it is not known whether the treatment of PHA-543613 affected the mRNA and protein expression in their brains. Another limitation of the biochemical part of the study was that because of the small amount of brain samples and the need for a larger of samples for ELISA than RT-PCR, the protein products were not measured for all targeted genes. Furthermore, there were discrepancies between the measured mRNA and protein levels. The non-significant difference in the protein levels of IL-1beta may result from lower sensitivity of ELISA than RT-PCR measurements. However, our results that showed higher expression of inflammatory factors IL-1beta and TNFalpha are in line with earlier data that showed increased IL-1beta and TNFalpha levels in the brains of aged mice [25]. Interestingly, the increase of pro-inflammatory cytokines mainly occurred in the hippocampus during aging both in our present study and earlier studies [25]. Another study showed that chronic systemic inflammation in aged rats induces pro-inflammatory microglial phenotype in the hippocampus and also impairs hippocampal LTP which can be restored by inhibiting microglial activation with minocycline [26]. It can be concluded that there may be a direct link between the impairment of LTP generation in the hippocampus and the impaired cognitive performance in behavioral tasks as a result of neuroinflammation. Pro-inflammatory cytokines also show elevated levels in human patients with age-related neurocognitive disorders. In patients with amnestic mild cognitive impairment and Alzheimer’s disease, IL-1beta is expressed in higher levels in the plasma, cerebrospinal fluid (CSF), and in certain brain regions, especially in the frontal cortex and hippocampus, and the concentration of IL-1beta negatively correlates with cognitive performance [27,28,29]. Expression of TNFalpha was also shown to be increased in the plasma and CSF during aging, and its elevated plasma level is associated with decreased brain gray matter volume [30, 31].
Interestingly, the decrease in the expression of BDNF was only detected at the protein level, and there was no difference in the mRNA expression. However, such discrepancies between BDNF mRNA and protein measurements were also found in another study [32]. Earlier studies also failed to detect a decrease in the BDNF mRNA expression in aged animals [33, 34]. Such findings imply post-translational mechanisms that limit the availability of BDNF protein in certain brain areas of aged rats. Furthermore, the age-related changes in BDNF mRNA expression are also unequivocal in human studies: one study showed a negative correlation between BDNF expression and age, while another study showed that BDNF mRNA expression is not different between young adult and aged individuals [35, 36]. However, a consensus seems to be about the age-related changes in BDNF protein levels, as more studies showed a decrease in serum BDNF protein levels during aging [37, 38]. Interestingly, in the early phase of Alzheimer’s disease, a transient increase was found in the serum BDNF levels, which significantly decreases during the progression of the disease in correlation with the severity of dementia [39].
In our study, we treated aged rats with the alpha7 nAChR agonist PHA-543613. In the MWM, we did not find a significant difference between the performance of vehicle- and PHA-543613-treated aged rats. However, a non-significant increase was seen in the average time spent in the target quadrant in the probe trial, and aged rats treated with 3.0 mg/kg PHA-543613 did not underperform young rats. This result indicates a slight improvement in MWM performance after the PHA-543613 treatment. Our findings are in line with previous studies that investigated the cognitive enhancer effects of alpha7 nAChR agonist compounds [13]. In a series of experiments, we have earlier demonstrated the cognitive enhancer effects of PHA-543613 in different tasks using the scopolamine-induced transient amnesia model where PHA-543613 improved spatial working memory performance of scopolamine-treated rats in the T-maze spontaneous alternation task [40]. Furthermore, PHA-543613 also improved the long-term memory of scopolamine-treated rats in the MWM task [20]. We have also shown that the cognitive enhancer effects of PHA-543613 are synergistic with the similar effects of NMDA antagonist anti-Alzheimer drug memantine since combinations of subeffective doses of PHA-543613 and memantine also improved cognitive performance in both the spontaneous alternation task and the MWM [20, 41]. In the present study, PHA-543613 also improved the reaction time of aged rats to unexpected stimuli in the PVT. This is the first time to report the effects of an alpha7 nAChR agonist in the PVT. An earlier study using another task (5-choice continuous performance task, 5C-CPT) for the investigation of attention implied that nicotine-induced improvement in attention and vigilance can be accounted for the activity of alpha4beta2 nAChRs rather than alpha7 nAChRs [42]. However, a more recent study demonstrated in the 5C-CPT that alpha7 nAChR partial agonist encenicline improves attention and vigilance in low-attentive rats [43]. Another partial agonist of the alpha7 nAChR ABT-126 was shown to improve attention/vigilance scores in a randomized, double-blind, placebo-controlled trial in human schizophrenia patients [44]. Thus, the present results in the PVT confirm earlier data that showed improvement in attention and vigilance by treatment with alpha7 nAChR agonists. Our behavioral findings are also in line with earlier electrophysiological studies where alpha7 nAChR agonist PHA-543613 enhanced neuronal processing in the prefrontal cortex which is importantly involved in executive functions [45].
Targeting alpha7 nAChRs is also relevant in the aspect of neuroinflammation. Alpha7 nAChRs are involved in the cholinergic anti-inflammatory system (for a review see [46]). There is a growing body of evidence showing that activation of alpha7 nAChRs improves cognitive functions and decreases the levels of brain pro-inflammatory factors at the same time. It was shown that the anti-inflammatory actions of nicotine and cotinine are dependent on the alpha7 subtype of nAChRs [47, 48]. Similarly, the anti-inflammatory effects of vagus nerve stimulation also require the activation of alpha7 nAChRs [49]. Selective compounds acting at the alpha7 nAChR were also shown to induce a variety of effects that decrease neuroinflammation and promote neuroprotective processes in the brain and the periphery. Alpha7 nAChR agonist PNU282987 decreases the levels of IL-1beta and TNFalpha in a rat model of chronic migraine and also decreases the number of astrocytes and microglia in the hippocampus [50]. Mice with cognitive impairment due to intracerebroventricular streptozotocin injection were not only improved in memory tests by alpha7 nAChR agonist GTS-21 but the drug also blocked the streptozotocin-induced overproduction of TNFalpha, IL-1beta, and IL-6 in the hippocampus and the cortex [51]. Alpha7 nAChR agonists also decrease IL-1beta levels and increase BDNF levels in mice with perioperative neurocognitive disorder [52]. Positive allosteric modulators (PAM) of the alpha7 nAChR also effectively reduce neuroinflammation. JWX-A0108 improved the learning and memory function of Alzheimer’s disease model APP/PS1 mice by decreasing the expression of TNFalpha, IL-1beta, and IL-6 and also decreasing the phosphorylation of NF-kappaB [53]. Activation of alpha7 nAChRs also has direct effects on glial cells involved in inflammatory processes. PNU120596 decreased the expression of activation markers in microglia and astrocytes [54]. Furthermore, PNU120596 also has a neuroprotective effect by the attenuation of LPS-induced production of quinolic acid from microglia in the hippocampus and the prefrontal cortex [55]. On the other hand, alpha7 nAChR agonist PNU282987 induces the release of neuroprotective heme oxygenase-1 from microglial cells [56]. Although as a limitation of the present study we did not directly investigate the effects of PHA-543613 on neuroinflammatory markers, it is reasonable to consider that the observed beneficial pharmacological effects on cognitive performance may be – at least partly – accompanied by the amelioration of the progressive neuroinflammation of aged animals. Future studies should be designed to address the effects of PHA-543613 or other alpha7 nAChR agonists on neuroinflammatory markers in the brain.
In conclusion, our results suggest that beyond the previously described memory enhancer effects, the activation of alpha7 nAChRs may also be an effective strategy to improve attention and vigilance in age-related cognitive impairments. Targeting alpha7 nAChRs is especially relevant in age-related cognitive deficits. Future studies may shed more light on the causal connection between age-related attention deficit and neuroinflammation and may facilitate the development of novel drugs with combined effects on cognitive performance and neuroinflammation in age-related disorders of the brain and the mind.
Data Availability
The authors declare that they make all experimental data available upon request to the corresponding author.
References
García-García VA, Alameda JP, Page A, Casanova ML. Role of Nf-Κb in ageing and age-related diseases: Lessons from genetically modified mouse models. Cells. 2021;10:1–29. https://doi.org/10.3390/cells10081906.
Alexander GE, Ryan L, Bowers D, Foster TC, Bizon JL, Geldmacher DS, Glisky EL. Characterizing cognitive aging in humans with links to animal models. Front Aging Neurosci. 2012;4:1–18. https://doi.org/10.3389/fnagi.2012.00021.
Gonzales MM, Garbarino VR, Pollet E, Palavicini JP, Kellogg DL, Kraig E, Orr ME. Biological aging processes underlying cognitive decline and neurodegenerative disease. J Clin Invest. 2022;132:1–10. https://doi.org/10.1172/JCI158453.
Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol Mech Dis. 2008;3:41–66. https://doi.org/10.1146/annurev.pathmechdis.2.010506.092044.
Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15:565–81. https://doi.org/10.1038/s41582-019-0244-7.
Mattson MP, Arumugam TV. Hallmarks of brain aging: Adaptive and pathological modification by metabolic states. Cell Metab. 2018;27:1176–99. https://doi.org/10.1016/j.cmet.2018.05.011.
Lana D, Ugolini F, Nosi D, Wenk GL, Giovannini MG. The emerging role of the interplay among astrocytes, microglia, and neurons in the hippocampus in health and disease. Front Aging Neurosci. 2021;13:651973. https://doi.org/10.3389/fnagi.2021.651973.
Angelova DM, Brown DR. Microglia and the aging brain: are senescent microglia the key to neurodegeneration? J Neurochem. 2019;151:676–88. https://doi.org/10.1111/jnc.14860.
Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2011;221:555–63. https://doi.org/10.1016/j.bbr.2010.11.058.
Bigl V, Arendt T, Fischer S, Fischer S, Werner M, Arendt A. † The cholinergic system in aging. Gerontology. 1987;33:172–80. https://doi.org/10.1159/000212872.
Gu Z, Wortwein G, Yu J, Perez-Polo JR. Model for aging in the basal forebrain cholinergic system. Antioxid Redox Signal. 2000;2:437–47. https://doi.org/10.1089/15230860050192215.
Bertrand D, Wallace TL. A review of the cholinergic system and therapeutic approaches to treat brain disorders. Curr Top Behav Neurosci. 2020;45:1–28. https://doi.org/10.1007/7854_2020_141.
Wallace TL, Bertrand D. Neuronal A7 nicotinic receptors as a target for the treatment of schizophrenia. Int Rev Neurobiol. 2015;124:79–111. https://doi.org/10.1016/bs.irn.2015.08.003.
Wallace TL, Porter RHP. Targeting the nicotinic Alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol. 2011;82:891–903. https://doi.org/10.1016/j.bcp.2011.06.034.
Corradi J, Bouzat C. Understanding the bases of function and modulation of A7 nicotinic receptors: implications for drug discovery. Mol Pharmacol. 2016;90:288–99. https://doi.org/10.1124/mol.116.104240.
Zdanowski R, Krzyzowska M, Ujazdowska D, Lewicka A, Lewicki S. Role of A7 nicotinic receptor in the immune system and intracellular signaling pathways. Cent Eur J Immunol. 2015;40:373–9. https://doi.org/10.5114/ceji.2015.54602.
Prickaerts J, Van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OAHH, Flood DG, Hilt D, Gawryl M, et al. EVP-6124, a novel and selective A7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of A7 nicotinic acetylcholine receptors. Neuropharmacology. 2012;62:1099–110. https://doi.org/10.1016/j.neuropharm.2011.10.024.
Deardorff WJ, Shobassy A, Grossberg GT. Safety and clinical effects of EVP-6124 in subjects with alzheimer’s disease currently or previously receiving an acetylcholinesterase inhibitor medication. Expert Rev Neurother. 2015;15:7–17. https://doi.org/10.1586/14737175.2015.995639.
Tadepalli SA, Kristóf Bali Z, Bruszt N, Nagy LV, Amrein K, Fazekas B, Büki A, Czeiter E, Hernádi I. Long-term cognitive impairment without diffuse axonal injury following repetitive mild traumatic brain injury in rats. Behav Brain Res. 2019;378:112268. https://doi.org/10.1016/j.bbr.2019.112268.
Bruszt N, Bali ZK, Tadepalli SA, Nagy LV, Hernádi I. Potentiation of cognitive enhancer effects of alzheimer’s disease medication memantine by Alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the morris water maze task. Psychopharmacology. 2021. https://doi.org/10.1007/s00213-021-05942-4.
Bali ZK, Bruszt N, Kőszegi Z, Nagy LV, Atlasz T, Kovács P, Csupor D, Csupor-Löffler B, Hernádi I. Aconitum Alkaloid Songorine Exerts Potent Gamma-Aminobutyric Acid-A Receptor Agonist Action In Vivo and Effectively Decreases Anxiety without Adverse Sedative or Psychomotor Effects in the Rat. Pharmaceutics. 2022;14:2067. https://doi.org/10.3390/pharmaceutics14102067.
The Jamovi Project. Jamovi (Version 2.2.5) 2023.
Grottick AJ, Haman M, Wyler R, Higgins GA. Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology. 2003;28:880–7. https://doi.org/10.1038/sj.npp.1300102.
Manuel AL, Foxe D, Bradshaw N, Cordato NJ, Hodges JR, Burrell JR, Piguet O. Sustained attention failures on a 3-min reaction time task is a sensitive marker of dementia. J Neurol. 2019;266:1323–31. https://doi.org/10.1007/s00415-019-09261-9.
Porcher L, Bruckmeier S, Burbano SD, Finnell JE, Gorny N, Klett J, Wood SK, Kelly MP. Aging triggers an upregulation of a multitude of cytokines in the male and especially the female rodent hippocampus but more discrete changes in other brain regions. J Neuroinflammation. 2021;18:1–19. https://doi.org/10.1186/s12974-021-02252-6.
Liu X, Wu Z, Hayashi Y, Nakanishi H. Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation. Neuroscience. 2012;216:133–42. https://doi.org/10.1016/j.neuroscience.2012.04.050.
Cacabelos R, Alvarez XA, Fernández-Novoa L, Franco A, Mangues R, Pellicer A, Nishimura T. Brain Interleukin-1 Beta in Alzheimer’s disease and vascular dementia. Methods Find Exp Clin Pharmacol. 1994;16:141–51.
Cacabelos R, Barquero M, García P, Alvarez XA, de Varela Seijas E. Cerebrospinal fluid interleukin-1 Beta (IL-1 Beta) in alzheimer’s disease and neurological disorders. Methods Find Exp Clin Pharmacol. 1991;13:455–8.
Rui W, Xiao H, Fan Y, Ma Z, Xiao M, Li S, Shi J. Systemic inflammasome activation and pyroptosis associate with the progression of amnestic mild cognitive impairment and alzheimer’s disease. J Neuroinflammation. 2021;18:1–14. https://doi.org/10.1186/s12974-021-02329-2.
Lindbergh CA, Casaletto KB, Staffaroni AM, Elahi F, Walters SM, You M, Neuhaus J, Contreras WR, Wang P, Karydas A, et al. Systemic tumor necrosis factor-alpha trajectories relate to brain health in typically aging older adults. J Gerontol - Ser A Biol Sci Med Sci. 2020;75:1558–65. https://doi.org/10.1093/GERONA/GLZ209.
Hu WT, Howell JC, Ozturk T, Gangishetti U, Kollhoff AL, Hatcher-Martin JM, Anderson AM, Tyor WR. CSF cytokines in aging, multiple sclerosis, and dementia. Front Immunol. 2019;10:1–8. https://doi.org/10.3389/fimmu.2019.00480.
Croll SD, Ip NY, Lindsay RM, Wiegand SJ. Expression of BDNF and TrkB as a function of age and cognitive performance. Brain Res. 1998;812:200–8. https://doi.org/10.1016/S0006-8993(98)00993-7.
Shao SH, Shi SS, Li ZL, Zhao MS, Xie SY, Pan F. Aging Effects on the BDNF MRNA and TrkB MRNA Expression of the Hippocampus in Different Durations of Stress. Chin J Physiol. 2010;53:285–93. https://doi.org/10.4077/CJP.2010.AMK056.
Lapchak PA, Araujo DM, Beck KD, Finch CE, Johnson SA, Hefti F. BDNF and TrkB MRNA Expression in the Hippocampal Formation of Aging Rats. Neurobiol Aging. 1993;14:121–6. https://doi.org/10.1016/0197-4580(93)90087-R.
Oh H, Lewis DA, Sibille E. The role of BDNF in age-dependent changes of excitatory and inhibitory synaptic markers in the human prefrontal cortex. Neuropsychopharmacology. 2016;41:3080–91. https://doi.org/10.1038/npp.2016.126.
Webster MJ, Weickert CS, Herman MM, Kleinman JE. BDNF MRNA expression during postnatal development, maturation and aging of the human prefrontal cortex. Dev Brain Res. 2002;139:139–50. https://doi.org/10.1016/S0165-3806(02)00540-0.
Erickson KI, Prakash RS, Voss MW, Chaddock L, Heo S, McLaren M, Pence BD, Martin SA, Vieira VJ, Woods JA, et al. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci. 2010;30:5368–75. https://doi.org/10.1523/JNEUROSCI.6251-09.2010.
Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, Virchow JC. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2005;26:115–23. https://doi.org/10.1016/j.neurobiolaging.2004.03.002.
Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K. Stage-dependent BDNF serum concentrations in Alzheimer’s disease. J Neural Transm. 2006;113:1217–24. https://doi.org/10.1007/s00702-005-0397-y.
Bali ZK, Inkeller J, Csurgyók R, Bruszt N, Horváth H, Hernádi I. Differential effects of Α7 nicotinic receptor agonist PHA-543613 on spatial memory performance of rats in two distinct pharmacological dementia models. Behav Brain Res. 2015;278:404–10. https://doi.org/10.1016/j.bbr.2014.10.030.
Bali ZK, Bruszt N, Tadepalli SA, Csurgyók R, Nagy LV, Tompa M, Hernádi I. Cognitive enhancer effects of low memantine doses are facilitated by an Alpha7 nicotinic acetylcholine receptor agonist in scopolamine-induced amnesia in rats. Front Pharmacol. 2019;10:73. https://doi.org/10.3389/fphar.2019.00073.
Young JW, Meves JM, Geyer MA. Nicotinic agonist-induced improvement of vigilance in mice in the 5-Choice continuous performance test. Behav Brain Res. 2013;240:119–33. https://doi.org/10.1016/j.bbr.2012.11.028.
Hayward A, Adamson L, Neill JC. Partial agonism at the Α7 nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive Rats. Eur Neuropsychopharmacol. 2017;27:325–35. https://doi.org/10.1016/j.euroneuro.2017.01.013.
Haig GM, Bain EE, Robieson WZ, Baker JD, Othman AA. A randomized trial to assess the efficacy and safety of ABT-126, a selective Alpha7 nicotinic acetylcholine receptor agonist, in the treatment of Cognitive impairment in schizophrenia. Am J Psychiatry. 2016;173:827–35. https://doi.org/10.1176/appi.ajp.2015.15010093.
Yang Y, Paspalas CD, Jin LE, Picciotto MR, Arnsten AFT, Wang M. Nicotinic Α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc Natl Acad Sci U S A. 2013;110:12078–83. https://doi.org/10.1073/pnas.1307849110.
Mizrachi T, Vaknin-Dembinsky A, Brenner T, Treinin M. Neuroinflammation modulation via Α7 nicotinic acetylcholine receptor and Its chaperone, Ric-3. Molecules. 2021;26:1–17. https://doi.org/10.3390/molecules26206139.
Tyagi E, Agrawal R, Nath C, Shukla R. Inhibitory role of cholinergic system mediated via Α7 nicotinic acetylcholine receptor in LPS-Induced neuro-inflammation. Innate Immun. 2010;16:3–13. https://doi.org/10.1177/1753425909104680.
Sadigh-Eteghad S, Vatandoust SM, Mahmoudi J, RahighAghsan S, Majdi A. Cotinine ameliorates memory and learning impairment in senescent mice. Brain Res Bull. 2020;164:65–74. https://doi.org/10.1016/j.brainresbull.2020.08.010.
Namgung U, Kim KJ, Jo BG, Park JM. Vagus nerve stimulation Modulates hippocampal inflammation caused by continuous stress in rats. J Neuroinflammation. 2022;19:1–15. https://doi.org/10.1186/s12974-022-02396-z.
Liu Q, Liu C, Jiang L, Li M, Long T, He W, Qin G, Chen L, Zhou J. Α7 nicotinic acetylcholine receptor-mediated anti-inflammatory effect in a chronic migraine rat model via the attenuation of glial cell activation. J Pain Res. 2018;11:1129–40. https://doi.org/10.2147/JPR.S159146.
Yamini P, Ray RS, Yadav S, Dhaliwal J, Yadav M, Kondepudi KK, Chopra K. Α7nAChR activation protects against oxidative stress, neuroinflammation and central insulin resistance in ICV-STZ induced sporadic Alzheimer’s disease. Pharmacol Biochem Behav. 2022;217:173402. https://doi.org/10.1016/j.pbb.2022.173402.
Wei P, Lyu W, Xu L, Feng H, Zhou H, Li J. Α7 nicotinic acetylcholine receptor may be a pharmacological target for perioperative Neurocognitive disorders. Front Pharmacol. 2022;13:1–10. https://doi.org/10.3389/fphar.2022.907713.
Li H, Gao J, Chang Y, Li K, Wang L, Ju C, Zhang F. JWX-A0108, a positive allosteric modulator of Α7 NAChR, attenuates cognitive deficits in APP/PS1 mice by suppressing NF-ΚB-mediated inflammation. Int Immunopharmacol. 2021;96: 107726. https://doi.org/10.1016/j.intimp.2021.107726.
Alzarea S, Rahman S. Alpha-7 nicotinic receptor allosteric modulator PNU120596 prevents lipopolysaccharide-induced anxiety, cognitive deficit and depression-like behaviors in mice. Behav Brain Res. 2019;366:19–28. https://doi.org/10.1016/j.bbr.2019.03.019.
Alzarea S, Abbas M, Ronan PJ, Lutfy K, Rahman S. The effect of an α-7 nicotinic allosteric modulator PNU120596 and NMDA receptor antagonist memantine on depressive-like behavior induced by LPS in mice: The involvement of brain microglia †. Brain Sci. 2022;12:11. https://doi.org/10.3390/brainsci12111493.
Parada E, Egea J, Buendia I, Negredo P, Cunha AC, Cardoso S, Soares MP, López MG. The microglial Α7-acetylcholine nicotinic receptor Is a key element in promoting neuroprotection by inducing heme Oxygenase-1 via nuclear factor erythroid-2-related factor 2. Antioxid Redox Signal. 2013;19:1135–48. https://doi.org/10.1089/ars.2012.4671.
Acknowledgements
Behavioral experiments were performed in collaboration with the Animal Facility at the Szentágothai Research Centre of the University of Pécs. We are grateful to Klára Lencse for animal care. Aged research animals were obtained by courtesy of Gedeon Richter Plc. (Budapest, Hungary).
Funding
Open access funding provided by University of Pécs. This research was funded by the National Research, Development, and Innovation Fund of the Hungarian Government (grant no. ‘K 129247’). The project TKP2021-EGA-10 was implemented with support provided by the National Research, Development, and Innovation Fund of Hungary financed under the TKP2021-EGA funding scheme. We also appreciate the funding from the Medical School Research Foundation of the University of Pécs (KA-2022–03). The funders had no role in the design of the study, in the collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
Author information
Authors and Affiliations
Contributions
ZKB: Conceptualization, Methodology, Investigation, Formal analysis, Visualization, Writing; LVN: Methodology, Investigation, Data curation, Writing; NB: Methodology, Investigation, Data curation; KB: Methodology, Investigation, Data curation; PE: Methodology, Data curation, Supervision, Resources; ZH: Investigation, Data curation; KG: Investigation, Data curation; SAT: Investigation, Data curation; IH: Conceptualization, Methodology, Writing, Supervision, Resources, Funding acquisition.
Corresponding author
Ethics declarations
Competing interest
The authors declare that there is no competing interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Bali, Z.K., Nagy, L.V., Bruszt, N. et al. Increased brain cytokine level associated impairment of vigilance and memory in aged rats can be alleviated by alpha7 nicotinic acetylcholine receptor agonist treatment. GeroScience 46, 645–664 (2024). https://doi.org/10.1007/s11357-023-01019-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11357-023-01019-6